Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CYPH with free AI briefings, catalyst countdowns, and dilution alerts.

CYPH · CYPHERPUNK TECHNOLOGIES INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$7.6M Cash on Hand
7.5mo Cash Runway
Follow CYPH by email Get an email when CYPH reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CYPH, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

CYPH holds $7.6M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.1M/quarter from operations, an estimated runway of 7.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 75 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CYPH files for a raise →

👥 Who Owns CYPH

Insiders 21.2% Other 5%+ holders 4% Institutions (76 holders) 44.6% Public and other holders 30.2%
HolderTypeShares% of sharesAs of
William Patrick III McEvoy
Chief Investment Officer, Director, 10% · +98.23M options
Insider 29,793,414 19.99% 2026-10-12
Winklevoss Capital Fund, LLC
10% owner · +154.41M options
Includes shares also reported by William Patrick III McEvoy, counted once
Insider 29,793,414 19.99% 2026-10-12
Severns Sean Michael 5%+ holder (13G) 6,000,000 4.03% 2025-11-12
Kevin Zhang
Head of Mining · +2.00M options
Insider 330,904 0.22% 2026-08-18
James H Cavanaugh
Director
Insider 168,963 0.11% 2026-03-13
Christian M Richard
Director · +75,000 options
Insider 168,750 0.11% 2026-03-13
Nissim Mashiach
Director · +75,000 options
Insider 168,750 0.11% 2026-03-13
William Li
Director · +75,000 options
Insider 168,750 0.11% 2026-03-13
Richard Schilsky
Director
Insider 168,750 0.11% 2026-03-13
Joseph Loscalzo
Director
Insider 168,750 0.11% 2026-03-13
Thomas John Dietz
Director · +100,000 options
Insider 132,500 0.09% 2026-08-26
Christopher Mirabelli
Director
Insider 130,376 0.09% 2026-03-26

Share count 149,041,593 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CYPH picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CYPH and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.